Harlan Korea Appoints New President - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Harlan Korea Appoints New President



Untitled Document

Kwan Goo Edmond (Ed) Cho, an industry veteran with experience in life sciences and pharmaceuticals, has been selected as the president of Harlan Korea.

As president, Cho will have full profit and loss responsibility and overall accountability for all aspects of the Harlan Contract Research Services (CRS) business stream serving the Korean chemical, agrochemical, and pharmaceutical markets.

Prior to joining Harlan CRS, Cho was director of market access and business development for Zuellig Pharma Korea, an $8 billion subsidiary of the Zuellig Group, providing contract services and clinical reach to multinational companies in more than 15 countries. He also held sales, marketing, and management positions during his 14 years with LG Life Sciences and served in the Special Forces of the Korean Army.

Cho earned a bachelor’s degree and Doctor of Veterinary Medicine degree from Seoul National University.

Source: Harlan

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here